JP Morgan Maintains Underweight on Agilon Health, Raises Price Target to $85
JP Morgan analyst Lisa Gill maintains Agilon Health (NYSE:AGL) with a Underweight and raises the price target from $31 to $85.
Stocks · News reference
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts upgraded various stocks, including BBY, BCE. See what other analysts think.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $146
Wells Fargo analyst Stephen Baxter maintains Agilon Health (NYSE:AGL) with a Overweight and raises the price target from $141 to $146.
Citigroup Upgrades Agilon Health to Neutral, Raises Price Target to $115
Citigroup analyst Daniel Grosslight upgrades Agilon Health (NYSE:AGL) from Sell to Neutral and raises the price target from $105 to $115.
Understanding Abercrombie (ANF) Reliance on International Revenue
Abercrombie & Fitch reported Q2 2026 total revenue of $1.27 billion, up 4.8% year-over-year. International markets contributed significantly, with Europe, Middle East and Africa generating $201.99 million (16% of total) and Asia Pacific contributing $44.16 million (3.5% of total). The company exceeded analyst expectations in both regions. ANF holds a Zacks Rank #1 (Strong Buy) rating, with stock gaining 49.1% over the past month and 97% over three months.
This Deere Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst
Argus Research Upgrades Abercrombie & Fitch to Buy, Announces $162 Price Target
Argus Research analyst Christine Dooley upgrades Abercrombie & Fitch (NYSE:ANF) from Hold to Buy and announces $162 price target.